Special Issue "Emerging Viral Infectious Diseases: Immunology, Therapeutics and Prevention in Post Pandemic Era"

A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Immunology and Immunotherapy".

Deadline for manuscript submissions: 15 January 2024 | Viewed by 1466

Special Issue Editor

Center for Immunology and Infectious Diseases, University of California, Davis, CA 95616, USA
Interests: SARS-CoV-2; infectious diseases immunology; HIV; Virus infectious diseases vaccinology; emerging infectious diseases; global one health; veterinary vaccines & diagnostics.
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

This Special Issue on “Emerging Viral Infectious Diseases: Immunology, Therapeutics and Prevention during a Post-Pandemic Era” is mainly focused on the study of the immunology, viral–host interaction, and immunotherapy of (re-)emerging viral infectious diseases in humans, animals, and mammals. 

The world experienced a deadly pandemic in 2020, and since then, the scientific world has mainly focused on the control, prevention, and study of the aftereffects of COVID-19. During this period, the study of existing/emerging viral diseases was given a lower priority. The pandemic has changed the disease incidence, immune responses, and mortality rates of various epidemic and endemic viral diseases, such as influenza virus, RSV, etc.

Further, re-emerging viruses have the tendency to mutate and infect unnatural hosts, leading to the emergence of new viral infections with the capacity to infect humans, animals, and other mammals, and eventually leading to pandemic conditions in the future similar to COVID-19. In the phase of preparation for future pandemics, it is necessary for the research community to study in detail the changes in mechanisms underlying virus mutation, virus–host interaction, viral immunology, possible treatment, and potent vaccine candidates for viral infections post-COVID-19. With the above considerations, it is the right time to invite scientific research articles from various disciplines to demonstrate the impact the pandemic has had on the changing immunology and virus–host interaction of infectious and tropical diseases involving viruses, to update our knowledge on the various new approaches that are being implemented in viral infectious diseases research across the globe. We welcome original articles and comprehensive reviews.

Dr. Yashavanth Shaan Lakshmanappa
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:


14 pages, 1769 KiB  
Evaluation of Safety and Potency of Kyasanur Forest Disease (KFD) Vaccine Inactivated with Different Concentrations of Formalin and Comparative Evaluation of In Vitro and In Vivo Methods of Virus Titration in KFD Vaccine
Biomedicines 2023, 11(7), 1871; https://doi.org/10.3390/biomedicines11071871 - 30 Jun 2023
Viewed by 1266
We evaluated the safety and potency of the Kyasanur Forest disease (KFD) vaccine inactivated with different formalin concentrations in mice, since the side effects due to higher formalin concentrations have been a major reason for vaccine refusal. Furthermore, with an objective to reduce [...] Read more.
We evaluated the safety and potency of the Kyasanur Forest disease (KFD) vaccine inactivated with different formalin concentrations in mice, since the side effects due to higher formalin concentrations have been a major reason for vaccine refusal. Furthermore, with an objective to reduce the use of mice in vaccine testing, we performed quantification of the KFD virus by real-time PCR and compared it with in vivo titration in mice. The KFD vaccine prepared in chicken embryo fibroblast cells was inactivated with 0.04%, 0.06%, and 0.08% concentrations of formalin. The vaccine inactivated with 0.04% and 0.06% formalin failed the safety test, whereas the KFD vaccine inactivated with 0.08% formalin was safe and potent with a log protective index of 5678 in mice. This reduced formalin content may induce no/lesser side-effects of pain/swelling which may increase the vaccine acceptance. The real-time PCR on individual KFD vaccine harvests interpreted that when the CT value of each harvest is <20, the vaccine will have sufficient viral particles to pass the potency test. Comparison of the real-time PCR on tenfold dilutions of the pooled harvests with in vivo mice inoculation test revealed that the 1MLD50 of the vaccine lies in the tenfold dilution that yields CT values between 31 and 34. Full article
Show Figures

Figure 1

Back to TopTop